Filtered By:
Vaccination: Cancer Vaccines
This page shows you your search results in order of relevance. This is page number 16.
Order by Relevance | Date
Total 479 results found since Jan 2013.
The Macro View – Health, Economics, and Politics and the Big Picture. What I Am Watching Here And Abroad.
August 04, 2022 Edition-----The war seems to grind on sadly and Pres. Biden is having a second round with COVID as unprecedented weather happens all over the US. It all feels rather like ‘the end of days’!In the UK we see an increasing chance of a third female PM being elected as the country seems to be struggling. We do need to remember however the UK remains a significant power with nuclear weapons and home-grown nuclear submarines!In OZ we have had last week working out how to progress the First Nations ‘Voice’ as we wrap up the 1st session of Parliament for the new Government. Comments welcome on how you think ...
Source: Australian Health Information Technology - August 4, 2022 Category: Information Technology Authors: Dr David G More MB PhD Source Type: blogs
Perception and safety analysis of COVID ‐19 vaccination in cancer patients: A multicenter, real‐world study
ConclusionDespite high levels of concern, COVID-19 vaccines were well tolerated by cancer patients, with a safety profile consistent with that of the general population.
Source: Cancer Medicine - November 14, 2022 Category: Cancer & Oncology Authors: Kyoungmin Lee,
In Hae Park,
Sang Cheul Oh,
Jae Hong Seo,
Min Ji Jeon,
Eun Sang Yu,
Dae Sik Kim,
Chul Won Choi,
Ah ‐reum Lim,
Myung Han Hyun,
Ju Won Kim,
Jwa Hoon Kim,
Yoon Ji Choi,
Soohyeon Lee,
Kyong Hwa Park,
Yeul Hong Kim,
Jung Yoon C Tags: RESEARCH ARTICLE Source Type: research
Janssen Presents Efficacy and Subgroup Analyses from MAIA Study Showing Long-Term Results of DARZALEX ® (daratumumab)-based Regimen in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
NEW ORLEANS, December 12, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new analyses from the Phase 3 MAIA study of DARZALEX® (daratumumab) in combination with lenalidomide and dexamethasone (D-Rd), evaluating progression-free survival (PFS), minimal residual disease (MRD) negativity and overall response rate (ORR) at a median follow-up of 64.5 months, and overall survival (OS) at a median follow-up of 73.6 months in newly diagnosed, transplant-ineligible (TIE) patients with multiple myeloma, regardless of patients’ age and across clinically important subgroups, as well as health...
Source: Johnson and Johnson - December 12, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Janssen Announces Unblinding of Phase 3 CARTITUDE-4 Study of CARVYKTI ® (cilta-cel) as Primary Endpoint Met in Treatment of Patients with Relapsed and Refractory Multiple Myeloma
RARITAN, New Jersey, January 27, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Phase 3 CARTITUDE-4 study evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) versus pomalidomide, bortezomib, and dexamethasone (PVd) or daratumumab, pomalidomide, and dexamethasone (DPd) for the treatment of patients with relapsed and lenalidomide-refractory multiple myeloma met its primary endpoint of significant improvement in progression-free survival (PFS) at the first pre-specified interim analysis. As a result of meeting the primary endpoint, the Independent Data Monitoring Commi...
Source: Johnson and Johnson - January 27, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention
RARITAN, N.J., February 13, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced plans to present more than 20 abstracts featuring seven oncology therapies from its robust portfolio and pipeline at the annual American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place in San Francisco on February 16-18. Building on more than a decade of leadership in the development of medicines for people diagnosed with GU cancers, Janssen will present data demonstrating its ambition to advance patient-centered treatment through precision medicine, real-world evidence a...
Source: Johnson and Johnson - February 13, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Janssen Presents Updated Data Demonstrating Improved Outcomes from the Use of Niraparib in Combination with Abiraterone Acetate Plus Prednisone as a First-Line Therapy in Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer
SAN FRANCISCO, February 16, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced updated results from the Phase 3 MAGNITUDE study evaluating the investigational use of niraparib, a highly selective poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with abiraterone acetate plus prednisone (AAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) with or without specific homologous recombination repair (HRR) gene alterations, including BRCA mutations. Results will be featured today in a Rapid Abstract Session (Abstract #170) at the American Society of Clinica...
Source: Johnson and Johnson - February 16, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Enlargement of a metastatic lymph node from differentiated thyroid cancer after COVID-19 vaccination
ConclusionsWe report the case of an enlargement of metastatic lymph node from differentiated thyroid cancer after COVID-19 vaccination. We warn clinicians to identify features of inflammatory response due to COVID-19 vaccination in order to prevent unwarranted surgical treatment.
Source: Endocrine - April 19, 2023 Category: Endocrinology Source Type: research
The Best of Highlight HEALTH 2012 – The Year in Review
As the year draws to a close, it’s become a tradition for us to take a look back at the top stories readers were interested in (this month, Highlight HEALTH celebrated it’s sixth year promoting advances in biomedical research). As we have in previous years, we’ve compiled two top ten lists of the most-viewed stories for 2012, one as measured by the absolute number of page views and the other as measured by the average number of page views per day posted.
To get a sense of underlying themes for the top ten lists, here’s a tag cloud of terms taken from articles that made the cut:
biomarker BMI brain can...
Source: Highlight HEALTH - January 1, 2013 Category: Medical Scientists Authors: Walter Jessen, Ph.D. Source Type: blogs
China Chops
China to Cut Prices of More Than 400 Drugs by Average 15%
China will cut the maximum retail prices of more than 400 varieties of drugs by an average 15 percent, including products from Pfizer Inc. (PFE), Novartis AG (NOVN) and Merck & Co. (MRK), to reduce health-care costs in the nation.
The changes, effective Feb. 1, will cover drugs used for respiratory diseases and pain relief, as well as other specialized medicines, the National Development and Reform Commission said in a statement on its website.
This is the fourth set of state-mandated price adjustments since 2011, with earlier cuts for drugs including antibiotics...
Source: PharmaGossip - January 8, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs
Smartphone apps miss a third of melanomas
Most apps wrongly called at least 30% of melanomas ‘unconcerning’Related items from OnMedicaNICE updates lung cancer guidanceParents unsure of HPV vaccine for daughters Cancer survivors need better diet advicePublic drastically underestimates cannabis risksSmoking may worsen cancer pain
Source: OnMedica Latest News - January 18, 2013 Category: UK Health Source Type: news
Another cancer we can prevent
Although no one talks about it much, one of the results of the AIDS epidemic has been that there has been an increase in the number of men diagnosed with anal cancer. This cancer arises in the anus, about a half-inch inside and above the opening. The first symptom is itching that doesn’t go away and then soreness and bleeding and finally, pain. In my practice, the only patients I saw with this were women. I wasn’t sure why until the discovery of HPV (Human Papilloma Virus). Not only is this the virus that causes cervical cancer and is sexually transmitted but now we know it also causes anal cancer. It isn’t clear wh...
Source: Dr.Kattlove's Cancer Blog - April 24, 2013 Category: Oncologists Source Type: blogs
Urgent Press Release: NY Assembly Voting to Give Vaccines to Minors Without Parent’s Permission
Conclusion
Please act now if you want to have a say in what vaccinations your children receive. These vaccinations are not as safe as the US government wants you to believe they are. If you are still not convinced, please watch the following two videos on the HPV vaccines.
Gardasil. One More Girl
Cervarix Video
References
1. http://assembly.state.ny.us/leg/?bn=A00497&term=…
2. http://www.greenmedinfo.com/anti-therapeutic-action/vaccination-hepatitis-b…
3. http://www.ageofautism.com/2009/02/managing-editors-note-below…
4. http://articles.mercola.com/sites/articles/archive/2013/01/24/hpv-vaccine-ave...
Source: vactruth.com - May 6, 2013 Category: Health Medicine and Bioethics Commentators Authors: Christina England Tags: Christina England Top Stories Adverse Events Diane Harper gardasil Hepatitis B vaccine HPV Vaccine New York Source Type: blogs
Nat’s first visit to an adult primary care physician
I took Nat to an adult primary care physician today — my own — for his annual checkup. We have loved our pediatrician for almost 20 years. She grew up with us. I learned from her all about childcare and she learned from me about autism care.
I thought that because Nat is now 23, he should be going to a doctor for adults. My doctor is a lovely man whom Ned and I both see and have for years, and I knew he’d be deft at handling an appointment with Nat. Now I know that using the words “deft” and “handling” implies that Nat is difficult at the doctor’s. No, far from it. He is a ...
Source: Susan's Blog - May 17, 2013 Category: Autism Authors: Susan Senator Tags: Uncategorized Source Type: blogs
HPV Vaccines Are Lowering Infection Rates Among Teenage Girls
The HPV vaccines may be controversial, but they are proving effective. A new study finds that the prevalence of the human papillomavirus, which can lead to cervical cancer, dropped by roughly half among teenage girls between the ages of 14 and 19 years old during the four years following the 2006 introduction of the first vaccine, the Gardasil shot that is sold by Merck (MRK).
The findings, which were published in The Journal of Infectious Diseases, are significant not only because it signals the vaccination campaign is apparently succeeding, but has also done so amid continual debate over the safety and veracity of the va...
Source: Pharmalot - June 20, 2013 Category: Pharma Commentators Authors: esilverman Source Type: blogs
